Some research suggests they may be particularly helpful for women with other hormonal issues, including insulin resistance and polycystic ovarian syndrome (PCOS)
This formulation is administered through a subcutaneous injection and should be taken on the same day each week
Such statements include, but are not limited to, statements regarding the offerings and services accessible on our platform, statements regarding future collaborations, functionality or expanded access to treatment options
The practical consequence: when in doubt, community sources cite using more bac water rather than less

Current FDA-Approved Weight Loss Medications: GLP-1 and Dual Agonists (Most Effective): Tirzepatide (Zepbound) Approval: November 2023 Mechanism: Dual GIP/GLP-1 receptor agonist Average Weight Loss: 15-22% of body weight Administration: Weekly injection Semaglutide (Wegovy) Approval: June 2021 Mechanism: GLP-1 receptor agonist Average Weight Loss: 10-15% of body weight Administration: Weekly injection Liraglutide (Saxenda) Approval: December 2014 Mechanism: GLP-1 receptor agonist Average Weight Loss: 5-8% of body weight Administration: Daily injection Older Weight Loss Medications (Less Effective): Phentermine-Topiramate (Qsymia) Approval: July 2012 Mechanism: Appetite suppressant + anticonvulsant Average Weight Loss: 7-9% of body weight Administration: Daily pill Naltrexone-Bupropion (Contrave) Approval: September 2014 Mechanism: Opioid antagonist + antidepressant Average Weight Loss: 4-5% of body weight Administration: Daily pill Orlistat (Xenical, Alli) Approval: April 1999 (prescription), 2007 (OTC) Mechanism: Lipase inhibitor (blocks fat absorption) Average Weight Loss: 3-5% of body weight Administration: Three times daily with meals Phentermine (Adipex-P, Lomaira) Approval: 1959 Mechanism: Appetite suppressant Average Weight Loss: 5-7% of body weight Administration: Daily pill Restriction: Short-term use only (12 weeks) Effectiveness Ranking: Why GLP-1 Medications Dominate: The top three most effective medications are all GLP-1 receptor agonists
